CO2022011467A2 - Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección - Google Patents

Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección

Info

Publication number
CO2022011467A2
CO2022011467A2 CONC2022/0011467A CO2022011467A CO2022011467A2 CO 2022011467 A2 CO2022011467 A2 CO 2022011467A2 CO 2022011467 A CO2022011467 A CO 2022011467A CO 2022011467 A2 CO2022011467 A2 CO 2022011467A2
Authority
CO
Colombia
Prior art keywords
polypeptides
infection
treat
development
limit
Prior art date
Application number
CONC2022/0011467A
Other languages
English (en)
Spanish (es)
Inventor
Neil P King
Carl Walkey
Jing Yang Wang
David Veesler
Alexandra C Walls
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of CO2022011467A2 publication Critical patent/CO2022011467A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CONC2022/0011467A 2020-02-14 2022-08-16 Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección CO2022011467A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US202063064235P 2020-08-11 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
CO2022011467A2 true CO2022011467A2 (es) 2022-10-31

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0011467A CO2022011467A2 (es) 2020-02-14 2022-08-16 Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección

Country Status (13)

Country Link
US (1) US20240277831A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103230A1 (cg-RX-API-DMAC7.html)
JP (1) JP7897796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220142472A (cg-RX-API-DMAC7.html)
CN (1) CN116096404A (cg-RX-API-DMAC7.html)
AU (1) AU2021221139A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016220A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167318A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011467A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022009860A (cg-RX-API-DMAC7.html)
PE (1) PE20230301A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
KR102689037B1 (ko) * 2022-07-12 2024-07-30 에스케이바이오사이언스 주식회사 SARS-CoV-2 백신 부스터 조성물
KR20250084945A (ko) * 2022-10-05 2025-06-11 유니버시티 오브 워싱턴 범사르베코바이러스 나노입자 백신
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Also Published As

Publication number Publication date
EP4103230A1 (en) 2022-12-21
PE20230301A1 (es) 2023-02-13
WO2021163438A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
KR20220142472A (ko) 2022-10-21
BR112022016220A2 (pt) 2022-10-25
JP2023513720A (ja) 2023-04-03
JP7897796B2 (ja) 2026-07-30
PH12022552099A1 (en) 2024-01-29
CA3167318A1 (en) 2021-08-19
CN116096404A (zh) 2023-05-09
US20240277831A1 (en) 2024-08-22
AU2021221139A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112022016220A2 (pt) Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção
BR112018004642A2 (pt) processo para tratamento capilar
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
DE602006021547D1 (de) Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
CO2022009532A2 (es) Nuevas composiciones de ácido modificado
PE20130588A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
BR112012033091A2 (pt) método de cimentação, e, composição de cimento
AR016368A1 (es) Agentes tensoactivos de sulfonato de alquilbenceno mejorados
MX2019013982A (es) Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).
MX2024000901A (es) Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria.
CL2012000683A1 (es) Composicion refrescante para reducir el mal olor que comprende 0,01 a 0,07% de polimero para mal olor que comprende polietilenimina homopolimerica; neutralizador del mal olor que comprende aldehido alifatico; un portador acuoso; en donde la composicion esta libre de material que ensucia o mancha telas; y metodo para reducir el mal olor.
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
AR062556A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
BRPI0509521A (pt) composições de pana de dpa alquiladas
BR112021006288A2 (pt) composição terapêutica, e, métodos para tratar um paciente e para tratar câncer.
JOP20220353A1 (ar) آلية إطلاق عطر، وطريقة لها واستخداماتها
ATE447929T1 (de) Selbstbräuner enthaltend wasserlösliche vitamin b3-komponente und bräunungswirkstoff mit alpha- hydroxycarbonyl-gruppierung
CO6592079A2 (es) Solución acuosa de polímero peine metacrílico fluido con un extracto seco superios a 60% proceso de fabircación y uso como agente fluidificante
AR070177A1 (es) COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL)
MX2024001301A (es) Anticuerpos y conjugados de anticuerpo especificos para nectina 4 y metodos de uso de los mismos.
ES2124865T3 (es) Dispersiones acuosas de ceras y siliconas, su obtencion y empleo.
CL2022002214A1 (es) Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección
AR129864A1 (es) Péptidos y métodos para uso en tratar el dolor
MX2013008955A (es) Nuevos peptidos implicados en la treyectoria de señale scf c-kit y composiciones que los contienen.
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação